ASCO 2021 Lung Cancer
Early-Stage NSCLC: Promising Data for Neoadjuvant Durvalumab with Stereotactic Body Radiotherapy
Jul 16, 2021
A recently published phase 2 study in Lancet Oncology showed that the combination of neoadjuvant durvalumab with stereotactic body radiotherapy (SBRT) is safe and grants a nearly 55% major pathologic response rates among...
Read MoreDurvalumab after chemoradiation proven safe in elderly NSCLC patients
Jul 14, 2021
The addition of durvalumab after chemoradiation (CRT) in unresectable stage 3 non-small cell lung cancer (NSCLC) can be safely delivered in elderly patients ≥70 years with comparable improvement in overall survival (OS), as...
Read MoreDoubling overall survival in US veterans with stage 3 non-small cell lung cancer
Jul 14, 2021
Median overall survival doubled for veterans with stage 3 non-small cell lung cancer who received chemoradiotherapy plus durvalumab, as compared to those receiving chemoradiotherapy alone, according to a new study presented at...
Read More5-year PACIFIC data hold strong in NSCLC
Jul 8, 2021
Updated findings of the PACIFIC trial showed an overall survival (OS) rate of 43% after 5 years of treatment with durvalumab, which has . Physician’s Weekly spoke with Dr. Camille Hertzka, vice president and head of Oncology, US...
Read More